RSV pre-fusion F protein vaccine

Respiratory syncytial virus (RSV) vaccine

Brand names: Abrysvo, Arexvy

The respiratory syncytial virus (RSV) vaccine is an active immunisation used to prevent RSV-associated lower respiratory tract disease, principally in older adults and in pregnancy to protect infants.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It presents the RSV fusion (F) protein in its prefusion conformation to stimulate a protective neutralising antibody response against the virus.

Prescribing in practice

Defer vaccination in anyone with a known severe allergic reaction to a previous dose or to a vaccine component.
It is given by intramuscular injection and should be offered according to the national immunisation programme eligibility.
When given in pregnancy, maternal antibodies transfer to the infant to provide early protection.

Monitoring

No routine laboratory monitoring is required; observe for immediate hypersensitivity after administration.

Counselling the patient

Mild injection-site soreness, tiredness or headache for a day or two is common.
Vaccination in pregnancy helps protect your baby in the first months of life.
Tell the vaccinator about any previous severe vaccine reactions.

Evidence & guidelines

RSV vaccination is recommended for eligible groups under the UK national immunisation programme.

Reference: UKHSA Green Book Ch.27a; JCVI; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Curated clinical cross-links plus same-class fallbacks.

Calculators

Pathways